3.22
  Price5.57%   +0.17
(After Hours: 3.16 -0.0600 -1.86%)
May-19-22 12:06PM Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual MeetingGlobeNewswire Inc.
May-16-22 04:49AM Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy ContestGlobeNewswire Inc.
May-11-22 04:15AM Athira Urges Shareholders to Support its Director Nominees at May 19 Annual MeetingGlobeNewswire Inc.
May-10-22 10:17AM Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022Benzinga
May-05-22 12:04PM Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director NomineesGlobeNewswire Inc.
May-04-22 06:46AM Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy CardGlobeNewswire Inc.
Apr-21-22 10:04AM Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2022Benzinga
Apr-20-22 09:02AM Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board RefreshmentGlobeNewswire Inc.
Apr-05-22 04:04AM Athira Files Definitive Proxy Statement and Mails Letter to ShareholdersGlobeNewswire Inc.
Mar-30-22 12:12PM Athira Pharma Highlights Strong Execution of Strategy and Positioning for the FutureGlobeNewswire Inc.
09:40AM Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?Zacks Investment Research
Mar-24-22 04:05AM Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical UpdateGlobeNewswire Inc.
08:10AM The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRLBenzinga
Mar-21-22 07:05AM Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of DirectorsGlobeNewswire Inc.
07:00AM Athira Pharma to Participate in Two Upcoming Investor ConferencesGlobeNewswire Inc.
Mar-20-22 04:50AM Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ CongressGlobeNewswire Inc.
Mar-14-22 07:00AM Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 CongressGlobeNewswire Inc.
Mar-02-22 02:15AM Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual MeetingGlobeNewswire Inc.
Feb-22-22 07:05AM Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual MeetingGlobeNewswire Inc.
Jan-31-22 07:00AM Athira Pharma Announces Appointment of Grant Pickering to its Board of DirectorsGlobeNewswire Inc.
Jan-25-22 07:00AM Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy BodiesGlobeNewswire Inc.
Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.
Cap:    |  Volume (24h):